Commercial Senju launches first-in-class dry eye disease drug in Japan PharmaphorumSenju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.CommercialOphthalmologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaphorum Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market. CommercialOphthalmologyRead full story Post navigation Previous: GSK again pulls application for leucovorin, touted by FDA as potential autism treatmentNext: With oral obesity race underway, all eyes are on Lilly’s Foundayo launch Related Stories Commercial Novo’s CEO champions “record-breaking start” for Wegovy pill in US market pharminent May 8, 2026 Commercial Novo hikes guidance on Wegovy pill’s fast sales start pharminent May 6, 2026 Commercial Novo’s Wegovy pill reaches 1M patients, shattering expectations with $355M in sales pharminent May 6, 2026
